κ-Opioid receptor effects of butorphanol in rhesus monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 1, 1999, Pages 259-265

  Vivian, Jeffrey A ^a   Deyoung, Michael B ^a   Sumpter, Tina L ^a   Traynor, John R ^a   Lewis, John W ^c   Woods, James H ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUTORPHANOL; CLOCINNAMOX; ETHYLKETAZOCINE; FENTANYL; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR ANTAGONIST; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALBUPHINE; QUADAZOCINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIURESIS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; FEMALE; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; URINE VOLUME;

ANALGESICS, OPIOID; ANIMALS; AZOCINES; BENZENEACETAMIDES; BUTORPHANOL; CINNAMATES; CONDITIONING, OPERANT; DISCRIMINATION LEARNING; DIURESIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHYLKETOCYCLAZOCINE; FEMALE; INJECTIONS, INTRAMUSCULAR; MACACA MULATTA; MALE; MORPHINE DERIVATIVES; NALBUPHINE; NARCOTIC ANTAGONISTS; PYRROLIDINES; RECEPTORS, OPIOID, KAPPA;

EID: 0032968071     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bickel WK, Bigelow GE, Preston KL and Liebson IA (1989) Opioid drug discrimination in humans: Stability, specificity and relation to self-reported drug effect. J Pharmacol Exp Ther 251:1053-1063.
2. 2 analysis on the respiratory depressant effects of alfentanil, etonitazene, ethylketocyclazocine (EKC) and Mr2033 in rhesus monkeys. J Pharmacol Exp Ther 264:145-151.
3. Butelman ER, Ko M-C, Sobczyk-Kojiro K, Mosberg HI, van Bemmel B, Zernig G and Woods JH (1998) Kappa-opioid receptor binding populations in rhesus monkey brain: Relationship to an assay of thermal antinociception. J Pharmacol Exp Ther 286:595-601.
4. Butelman ER, Negus SS, Lewis JW and Woods JH (1996) Clocinnamox antagonism of opioid suppression of schedule-controlled responding in rhesus monkeys. Psychopharmacology 123:320-324.
5. Butelman ER, Winger G, Zernig G and Woods JH (1995) Butorphanol: Characterization of agonist and antagonist effects in rhesus monkeys. J Pharmacol Exp Ther 272:845-853.
6. Dykstra LA, Gmerek DE, Winger G and Woods JH (1987) Kappa opioids in rhesus monkeys: I. Diuresis, sedation, analgesia and discriminative stimulus effects. J Pharmacol Exp Ther 242:413-420.
7. 6 glioma cell line expressing the μ opioid receptor. J Pharmacol Exp Ther 278:1121-1127.
8. Feng YZ, Rockhold RW and Ho IK (1997) Nor-binaltorphimine precipitates withdrawal and excitatory amino acid release in the locus ceruleus of butorphanol -but not morphine-dependent rats. J Pharmacol Exp Ther 283:932-938.
9. Garner HR, Burke TF, Lawhorn CD, Stoner JM and Wessinger WD (1997) Butorphanol-mediated antinociception in mice: Partial agonist effects and mu receptor involvement. J Pharmacol Exp Ther 282:1253-1261.
10. Gerak LR, Butelman ER, Woods JH and France CP (1994) Antinociceptive and respiratory effects of nalbuphine in rhesus monkeys. J Pharmacol Exp Ther 271:993-999.
11. Gerak LR and France CP (1996) Discriminative stimulus effects of nalbuphine in rhesus monkeys. J Pharmacol Exp Ther 276:523-531.
12. Jaw SP, Makimura M, Hoskins B and Ho IK (1993) Effects of nor-binaltorphimine on butorphanol dependence. E J Pharmacol 239:133-140.
13. Leander JD (1983) Evidence that nalorphine, butorphanol and oxilorphan are partial agonists at a kappa-opioid receptor. Eur J Pharmacol 86:467-470.
14. Liguori A, Morse WH, Bergman J (1996) Respiratory effects of opioid fall and partial agonists in rhesus monkeys. J Pharmacol Exp Ther 277:462-472.
15. Mamoon AM, Barnes AM, Ho IK and Hoskins B (1995) Comparative rewarding properties of morphine and butorphanol. Brain Res Bull 38:507-511.
16. Negus SS, Burke TF, Medzihradsky F and Woods JH (1993) Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: Antagonism by quadazocine. J Pharmacol Exp Ther 267:896-903.
17. 3 analgesic in mice. J Pharmacol Exp Ther 262:1044-1050.
18. Preston KL, Bigelow GE, Bickel WK and Liebson IA (1989) Drug discrimination in human postaddicts: Agonist-antagonist opioids. J Pharmacol Exp Ther 250:184-196.
19. Preston KL, Bigelow GE and Liebson IA (1990) Discrimination of butorphanol and nalbuphine in opioid-dependent humans. Pharmacol Biochem Behav 37:511-522.
20. 6 glioma cell line stably expressing the human kappa opioid receptor. J Pharmacol Exp Ther 288:827-833.
21. Steinfels GF, Young GA and Khazan N (1982) Self-administration of nalbuphine, butorphanol and pentazocine by morphine post-addict rats. Pharmacol Biochem Behav 16:167-171.
22. 2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats. J Pharmacol Exp Ther 271:959-968.
23. Walker EA, Richardson TM and Young AM (1997) Tolerance and cross-tolerance to morphine-like stimulus effects of mu opioids in rats. Psychopharmacology 133:17-28.
24. Young AM, Stephens KK, Hein DW and Woods JH (1984) Reinforcing and discriminative stimulus properties of mixed agonist-antagonist opioids. J Pharmacol Exp Ther 229:118-126.
25. Zernig G, Burke T, Lewis JW and Woods JH (1996) Mechanism of clocinnamox blockade of opioid receptors: Evidence from in vitro and ex vivo binding and behavioral assays. J Pharmacol Exp Ther 279:23-31.
26. Zernig G, Lewis JW and Woods JH (1997) Clocinnamox inhibits the intravenous self-administration of opioid agonists in rhesus monkeys: Comparison with effects on opioid agonist-mediated nociception. Psychopharmacology 129:233-242.
27. 35S]GTPγS binding to membranes: Determination of potencies and efficacies of ligands. J Pharmacol Exp Ther 282:676-684.